A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145228 in Healthy Volunteers

Trial Profile

A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145228 in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2018

At a glance

  • Drugs ACH-0145228 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions; First in man
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 10 Jul 2018 According to an Achillion Pharmaceuticals media release, the company expects to report interim results in the second half of 2018.
    • 22 Feb 2018 According to an Achillion Pharmaceuticals media release, results of this study are expected in fourth quarter 2018.
    • 20 Dec 2017 According to an Achillion Pharmaceuticals media release, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top